Jeffrey Schwartz is a Managing Director of Bain Capital Life Sciences, where he is a founding member of the team. Prior to co-founding Bain Capital Life Sciences in 2016, he was a leader within the healthcare vertical of Bain Capital Private Equity. He currently is a board member of Hugel, QuVa Pharma, and Springworks Therapeutics. Since joining Bain Capital, Mr. Schwartz has been actively involved in a wide spectrum of healthcare companies in which Bain Capital Private Equity has made investments
Prior to joining Bain Capital, Mr. Schwartz served as an Equity Research Analyst at Lehman Brothers, working in both New York and London.
Mr. Schwartz received an MBA from The Wharton School at the University of Pennsylvania, where he was a Palmer Scholar. He graduated magna cum laude from Yale University with a BA in economics.
Rob has more than 20 years of leadership experience. Before joining Rapid Micro Biosystems, he was Vice President and General Manager, Americas, for the Microbiology Division of Thermo Fisher Scientific.
Previously, Rob was the VP of Global Strategy, Marketing, and Business Development for Fisher Scientific. He’s also held senior positions at McKesson Corporation and its affiliates, including EVP Operations and Development and National Vice President of Sales and Business Development.
Earlier in his career, Rob was a senior consultant within the Life Sciences and Healthcare practice of Deloitte Consulting and an aviation officer with the U.S. Army.
Rob holds a BS in Economics from the United States Military Academy at West Point and an MBA from Columbia University, where he was the Dr. Donald Bibeault Scholar
Mr. Cashman is a co-founder of Protez Pharmaceuticals Inc. and most recently served as Director, President, and CEO. Protez was acquired by Novartis in 2008.
He has 30 years of experience in the pharmaceutical industry including prior roles as President and CEO, Message Pharmaceuticals, and as Vice President, Sales and Marketing, for both Pfizer and SmithKline Beecham.
Mr. Cashman also serves on the board of directors of the Science Center, Noble Biomaterials, Marinus Pharmaceuticals, and MBF Therapeutics.
David Hirsch is a founder and Managing Director of Longitude Capital. He focuses on investments in biotechnology. From 2005 to 2006, Dr. Hirsch was a Vice President of Pequot Ventures where he worked in the life sciences practice.
Prior to Pequot, Dr. Hirsch was an Engagement Manager in the pharmaceutical practice of McKinsey & Company. While at McKinsey, he worked with many large pharmaceutical companies across a range of projects including clinical and commercial strategies, M&A evaluations, portfolio prioritization, and managed care strategy.
Dr. Hirsch currently serves on the boards of Civitas Therapeutics and Precision Therapeutics and is a board observer at InfaCare Pharmaceuticals and Xanodyne Pharmaceuticals. He is also actively involved with Longitudes's investments in Amarin (NASDAQ: AMRN) and Corcept Therapeutics (NASDAQ: CORT), as well as prior investments in Horizon Therapeutics and Sequenom (NASDAQ: SQNM).
Dr. Hirsch holds a Ph.D. in Biology from Massachusetts Institute of Technology, and MD from Harvard Medical School, and a BA in Biology from The Johns Hopkins University.
Dr. Marengère is a Managing Partner with TVM Capital Life where he oversees the implementation of Canadian operations and North American investment strategy and co-manages the relationship with strategic partner Eli Lilly. Dr. Marengère joined TVM in 2011 and has more than 20 years of venture capital experience. He has overseen a number of investments on behalf of TVM and is a Director on the Boards of Ixchelsis Ltd; PRCL Pharma; Aurka Pharma; Panthera Dental Inc.; FAAH Pharma; Kaneq Biosciences; Acer Therapeutics; and TeserX Pharma. Luc was also a Director on the Board of Colucid Pharma which sold to Eli Lilly in March 2017.
Prior to Joining TVM Capital, Luc was a Managing General Partner with VG Partners where he founded and ran the VG Advanced Life Sciences Fund. Luc was a Director on the Boards of Trillium Technologies Inc.; Cytochroma Inc.; Aegera Therapeutics, Inc.; Cita Neuropharma; and lastly Argos Therapeutics Inc. Luc also invested in VisualSonics, Inc.
Prior to joining VG Partners, Luc focused on making venture investments in the life science sector while with Caisse De Depot Capital - Technology Ventures and MDS Capital Corp. Prior to his venture capital career, he conducted commercially oriented research in the fields of immunology and oncology while at Amgen.
Luc holds a Ph.D. from University of Toronto’s Department of Medical Biophysics and Molecular Genetics.
Sherrill Neff is a founder and partner of Philadelphia-based Quaker Partners, which manages healthcare venture capital funds with over $700 million in assets.
Prior to forming Quaker Partners, he was President, Chief Operating Officer, and a Director of Neose Technologies, Inc., a publicly traded biotechnology company that was initially formed by the University of Pennsylvania.
Previously, Mr. Neff was a Senior Vice President at U.S. Healthcare, Inc., a leading publicly traded managed care organization (acquired by Aetna). Mr. Neff was formerly a Managing Director, specializing in equity finance and mergers and acquisitions, and co-head of the financial institution’s group of the investment banking division of Alex. Brown & Sons.
He currently sits on the boards of directors of four Quaker Partners portfolio companies (including Rapid Micro Biosystems): Cempra (Nasdaq: CEMP), a biotechnology company developing novel antibiotics; Intact Vascular, a medical technology company developing novel devices for peripheral arterial disease; and Vesper Medical, a medical technology company developing novel devices for peripheral venous disease.
Sherrill Neff is a graduate of Wesleyan University and a magna cum laude graduate of the University of Michigan Law School.
Mr. Ricciardi spent his entire 39-year career at Pfizer Inc., retiring in 2011. At retirement, Nat held the positions of President, Pfizer Global Manufacturing and Senior Vice President, Pfizer Inc.
In addition to his corporate leadership role, Nat was directly responsible for all of Pfizer’s internal and external supply organization, a global enterprise with as many as 38,000 employees and more than 100 manufacturing facilities supplying small and large molecule pharmaceuticals, vaccines, consumer, nutrition and animal health products.
He played a leadership role in shaping a mission-driven and values-based culture as the company went through phases of growth, mergers, and acquisitions and transformation. His relentless focus on Quality and Compliance became a competitive advantage.
Mr. Ricciardi earned a degree in Chemical Engineering from the City College of New York (CCNY) and an MBA in Finance and International Business from Fordham University. He serves on the Board of Directors of Dynavax Technologies, Inc., Asterias Biotherapeutics, Inc., and is on the Strategic Advisory Board of HealthCare Royalty Partners. He is currently a member of the Board of the 21st Century Foundation of CCNY.